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The Kras Mutational Spectra of Chemically Induced Lung
Tumors in Different Inbred Mice Mimics the Spectra of
KRAS Mutations in Adenocarcinomas in Smokers versus
Nonsmokers
Jason M. Fritz, BS, Lori D. Dwyer-Nield, PhD, Bridgette M. Russell, BS,
and Alvin M. Malkinson, PhD
Background: Human lung cancer patients exhibit different KRAS
mutations depending on smoking status. In a mouse model of human
cancer, A/J and BALB/cBy mice treated with the tobacco carcino-
gen, 3-methylcholanthrene (MCA), followed by butylated hydroxy-
toluene (BHT)-elicited chronic inflammation develop a high multi-
plicity of lung tumors.
Methods: DNA was isolated fromMCA-induced lung tumors in A/J
and BALB/cByJ mice. Kras codon 12 sequences from these tumors
were compared to those in human lung tumors from smokers and
never-smokers.
Results: The distribution of Kras codon 12 mutations in MCA-
induced A/J lung tumors is strikingly similar to those found in
adenocarcinomas from human smokers. In contrast, codon 12 mu-
tations in BALB/cBy mice contain predominantly G¡ Dmutations,
which is the most common mutation in never smokers.
Conclusions: A single lung carcinogen induces different tumor
initiating mutations in different strains of mice. This may be useful
for investigating the role of specific KRAS mutations in adenocar-
cinoma pathogenesis in smokers versus never smokers, identifying
mechanisms that select for certain KRASmutations and developing new
drugs that specifically target cells with different KRAS mutations.
Key Words: Kras mutations in lung cancer, Smokers and nonsmok-
ers, Mouse models of human adenocarcinoma, Genetic background
determines mutations, Strain susceptibilities to Kras mutations.
(J Thorac Oncol. 2010;5: 254–257)
Adenocarcinoma (AC), the most common form of lungcancer, is heterogeneous with respect to growth patterns,
histogenesis, malignant behavior, and molecular characteris-
tics. For example, in addition to etiologic differences in
environmental causation, gender, and ethnicity, AC in smok-
ers versus never smokers is distinguished by patient progno-
sis and therapeutic responsiveness.1 Twenty-five percent of
AC in smokers and 15% of AC in never smokers bear a
spectrum of KRAS base substitutions at codon 12.2 However,
it is not clear how specific KRAS mutations direct survival
outcome in smokers and never smokers. Mutant Kras proteins
resistant to hydrolysis of the activating GTP ligand adopt a
constitutively active conformation, leading to dysregulation
of several downstream signaling pathways including MAP
kinases, phosphatidyl inositol 3 kinase, and protein kinase C.
Such hyperactive Kras signaling results in increased tumor
cell proliferation, decreased apoptosis, invasion of local tis-
sue, and stimulation of cancer-associated inflammation.3
Lung tumors arise in mice spontaneously and can also
be induced with chemicals, transgenic oncogenes, viruses,
and radiation.4 These tumors have morphologic and molecu-
lar features similar to human AC, providing models that can
be experimentally manipulated to resolve questions concern-
ing AC development. In two-stage carcinogenesis, an initiat-
ing agent causes a mutation, and chronic application of a
noncarcinogenic promoting agent clonally expands these ini-
tiated cells.4 Metabolites of 3-methylcholanthrene (MCA), a
polycyclic aromatic hydrocarbon formed by carbon pyrolysis
and found in tobacco smoke and tar, mutate Kras at codon 12.5
MCA treatment of A/J mice induces 5.4 tumors/mouse
with 100% incidence, whereas MCA-treated balb/cBy (here-
after cBy) mice only develop 0.4 tumors/mouse, with 44%
incidence.6,7 When MCA treatment is followed by repeated
exposure to the noncarcinogenic pneuomotoxin, butylated
hydroxytoluene (BHT), A/J and cBy develop 23 and 25
tumors/mouse, respectively, with 100% incidence in both
strains. This MCA/BHT protocol results in a similar ratio of
lung adenomas and ACs 20 weeks after carcinogen adminis-
tration in both of these strains. AC incidence increases be-
tween 20 and 42 weeks, with no significant change in tumor
multiplicity, indicating that these lung adenomas are precur-
sor lesions for mouse lung AC.4 BHT exerts its promoting
effect mainly by inducing macrophage infiltration and induces
similar degrees of macrophage infiltration in both strains.6 Dif-
ferences in the frequency and nature of Kras mutations are
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dependent on genetic background, gender, carcinogen, and
method of carcinogen exposure.8 For instance, lung tumors
induced by urethane exhibit frequencies of codon 61 Kras
mutations in lung tumors that reflect the relative susceptibilities
of inbred strains to lung tumor development,9 whereas transpla-
cental carcinogenesis with N-ethylnitrosourea at different gesta-
tional stages shifts Kras mutations from codon 12 to 61.10 In
comparing the nature of Kras codon 12 mutations induced by
MCA/BHT in A/J and cBy mice, we found a correlation be-
tween strain-dependent mutations with those in human smokers
versus never smokers.
MATERIALS AND METHODS
Human KRAS Mutation Incidence
Incidence of KRAS mutations in human lung AC was
obtained from the Catalogue of Somatic Mutations in Cancer
(COSMIC) database in September 2009, using the search
terms: “Lung, all subtissue, carcinoma histology, and adeno-
carcinoma subhistology” but was not stratified with respect to
patient smoking history.11 KRAS mutation incidence in
smoker (current and former) versus never-smoker lung AC in
the “selected studies” was adapted with permission from
Riely et al.,2 Gealy et al.,12 and Wu et al.13
Lung Tumorigenesis and DNA Isolation in Mice
Lung tumorigenesis was initiated in 17 A/J and 16 cBy
mice by a single intraperitoneal MCA injection (10 g/g in
A/J and 15 g/g in cBy). In nine A/J and 12 cBy mice, MCA
treatment was followed by 6 weekly intraperitoneal BHT
injections (150 mg/g, week 1; 200 mg/g thereafter), as de-
scribed.6,7 DNA was isolated from 68 A/J and 67 cBy
tumors,8 an average of 4 tumors/mouse, harvested 20 weeks
after MCA initiation. At this time point, 26% of A/J and 35%
of cBy tumors are AC, and the remainder are adenomas,
according to the pathologic criteria of Nikitin et al.14 AC
incidence was similar between A/J and cBy mice (Fisher’s
exact test, two sided, p  0.5587). All animal procedures
were approved by the Institutional Animal Care and Use
Committee of the University of Colorado Denver.
Kras Polymerase Chain Reaction and Sequencing
Exon 1 was amplified by GoTaq polymerase (Promega;
Madison, WI) as described previously,15 using a stepwise-
increasing polymerase chain reaction thermocycling profile.
FIGURE 1. Incidence and nature of Kras mutations in lung
tumors. Mutation incidence by codon (mutation type/total
no. of mutations analyzed), the resulting amino acid substi-
tution, and color-coded amino acid group functionality
(gray  hydrophobic, red  acidic, neutral  uncharged,
and blue  basic) are shown. The total number of tumors
containing mutations at each codon is represented at the
top of each column. A, KRAS mutation incidence in 1132
human lung adenocarcinoma (AC) from the Catalogue of
Somatic Mutations in Cancer (COSMIC) database is compa-
rable with the 129 combined smokers and never smokers
mutations reported in Refs. 2, 12, and 13. B, C, Incidence of
3-methylcholanthrene (MCA)-induced Kras mutations in 16
cBy (B) and 17 A/J (C) mice is similar to those in human
never smokers and smokers (current and former), respec-
tively. aMurine lung tumors were lung adenomas or AC as
defined in “Materials and Methods” section, whereas all hu-
man lesions were lung AC. KRAS mutation incidence in
smokers and never smokers in the “selected studies”
is adapted with permission from Clin Cancer Res. 2008;
14:5731, Table 3; Cancer Epidemiol Biomarkers Prev. 1999;8:
300, Table 2; and Cancer. 2008;113:3202. Data from Wu et
al. are copyright (2008) American Cancer Society, and this
material is reproduced with permission from Wiley-Liss, Inc.,
a subsidiary of John Wiley & Sons, Inc.
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The presence of a single band (110 bp) was verified and
polymerase chain reaction products sequenced by the University
of Colorado Cancer Center Core Facility as described.8
RESULTS
Tumors from A/J and cBy mice displayed different
Kras mutations that were remarkably similar to the variations
in mutation spectrum reported in smokers and never smokers,
respectively (Figure 1). The COSMIC database has accumu-
lated 9X the amount of combined data as that reported in the
aforementioned “selected studies” that compare KRAS muta-
tions in smokers versus never smokers, but the smaller pool
of patient data in these “selected studies” is a representative
subset of the larger population of patients with AC (Figure
1A). MCA induced Kras mutations in 97% of the cBy and
85% of the A/J tumors (data not shown). The Kras codon 12
mutational spectrum of 65 MCA-induced lung tumors in 16
cBy mice was very similar to that found in AC of human
never smokers (Figure 1B), whereas the Kras mutational
spectrum of 58 tumors in 17 A/J mice was very similar to that
found in AC of smokers (Figure 1C). In both never smokers
and MCA-induced cBy tumors, most of Kras mutations were
G3D transitions. In smokers and A/J tumors, the most common
amino acid substitutions were G3V and G3C transversions,
with a few G3D transitions in both mice and humans. Both
mouse strains had a similar incidence of G3R transversions,
whereas never smokers had a few G3S and smokers a few
G3A transversions. The G3R transversion is also present in
the larger COSMIC human database (Figure 1A). The few codon
13 mutations in each mouse strain were G3R transitions; in
cBy mice, these only appeared in tumors that also contained
mutations at codon 12. No codon 13 mutants were reported in
never smokers, whereas a few G3C and G3V codon 13
mutations were detected in smokers.
DISCUSSION
Mechanistically, differences in Kras mutations could
be due to variations in MCA metabolism and/or DNA repair.
The different allelic backgrounds of A/J versus cBy mice may
portend a greater likelihood of transitions in cBy mice
(G123D and G13 3R) versus transversions (all other mu-
tations) due to the formation of different MCA metabolites.
MCA can be converted to multiple distal metabolites and
form different DNA adducts among diverse inbred strains.16
The composition of DNA repair enzymes may diverge be-
tween A/J and cBy mice; if so, this would alter the likelihood
of repairing transitions versus transversions. Whatever the
cause of AC in never smokers, the resulting pattern of KRAS
mutations is similar to that resulting from MCA/BHT treat-
ment of cBy mice. Transfecting different KRAS mutants into
NIH3T3 fibroblasts caused differential responsiveness to
toxic agents such as hydrogen peroxide and formaldehyde,17
implying that different KRAS mutations can generate differ-
ences in either downstream enzyme activity or binding affin-
ity to other effector proteins.
Apart from EGFR mutation status, differences in KRAS
mutations are among the few molecular differences known to
distinguish AC in smokers from never smokers. This genetic
mouse model in which MCA-induces Kras mutations in one
strain similar to those of smokers, whereas the same carcin-
ogen exposure induces Kras mutations corresponding to
those of never smokers in another strain, should be useful in
unraveling effects of different Kras mutations on downstream
signaling pathways. Polymorphisms in the Pas1 locus on Chr
6, which includes Kras,4 constitute a major genetic determi-
nant of lung tumor susceptibility in mice and are also asso-
ciated with increased risk for developing AC in humans.18
A/J and cBy mice have the same sensitive Kras haplotype, so
other loci presumably are responsible for generating their
distinct arrays of Kras mutations. We recently showed using
chromosome substitution strains that genes mapping to chro-
mosomes other than Chr 6 influence the nature of Kras codon
61 mutations in lung tumors induced by urethane.7
Phase II trials using yeast vaccines against different
codon 12 KRAS mutations are ongoing.19 However, because
never smokers and smokers exhibit different KRAS muta-
tions, each patient population may require different vaccines.
The ability to generate the human smoker and nonsmoker
profiles of Kras mutations in mice facilitates preclinical
optimization of these molecular-targeted cancer therapies.
In light of increasing information segregating AC in
smokers and never smokers into molecularly separable diseases,
the evolution of more specific animal models can accelerate our
understanding of differences between these discrete populations.
Our data suggest that carcinogen-induced mouse AC models are
useful means to better understand the genetic underpinnings of
lung cancer, which may improve detection and clinical outcome.
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